K
Korro Bio
Efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms
About Korro Bio
Korro Bio is a cutting-edge biotechnology startup focused on developing innovative RNA-based therapies to treat debilitating and life-threatening diseases. The company operates in the biopharmaceutical market, targeting patients who suffer from conditions that currently have limited or no treatment options. Korro Bio's unique approach leverages RNA editing, a method that allows for precise modifications at the RNA level to alter protein function. This technique is considered superior to traditional gene editing and gene therapy because it can make single base edits, which are more accurate and potentially less risky.
The business model of Korro Bio revolves around the discovery, development, and commercialization of these RNA therapies. The company invests heavily in research and development (R&D) to create new treatments based on scientific insights and human genetics. Once a therapy is developed, Korro Bio aims to bring it to market either independently or through partnerships with larger pharmaceutical companies. Revenue is generated through the sale of these therapies, licensing agreements, and potentially through collaborations with other biotech firms.
Korro Bio serves a diverse range of clients, including healthcare providers, hospitals, and patients who are in dire need of new treatment options. The company also collaborates with academic institutions and research organizations to advance its scientific discoveries.
In summary, Korro Bio is at the forefront of RNA editing technology, striving to transform the future of medicine by providing new hope for patients worldwide. The company is driven by a mission to make groundbreaking scientific advancements accessible and effective for those suffering from severe diseases.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2018
- Headquarters
- Cambridge, United States
- Listing
- IPO 2023
- Employees
- 75
- Open positions
- 7
- Dealroom signal
- 64.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, Woman Founder, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Jul 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Mar 2026 | $85M | — | Nantahala Capital Management · Kalehua Capital Management · NEA · Venrock | ↗ |
| PRIVATE PLACEMENT VCOther financing | Apr 2024 | $70M | — | Atlas Venture · Deep Track Capital · Blue Owl Capital · NEA | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $6.4M | 0% | −$49M | -759.5% |
| 2025 | $6.4M | +181.5% | −$49M | -759.5% |
| 2024 | $2.3M | — | −$88M | -3890.1% |
| 2023 | $0 | — | −$81M | — |
| 2022 | $0 | — | −$55M | — |
| 2021 | $0 | — | −$34M | — |
Growth signals
Latest recorded traffic for Korro Bio is 4.9K monthly website visits, down 10.9% over the last three months. Korro Bio's team declined 21.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Series A14 investors entered at this stage
- WCWu Capital
Cormorant Asset Management
Qiming Venture Partners USA
MP Healthcare Venture Management
Alexandria Venture Investments
Citadel
Eventide Asset Management
Fidelity Investments
Monashee Investment Management- VMVerition Fund Management
Sixty Degree Capital
Surveyor Capital
Invus
Point72
Series B and later8 investors entered at this stage
- NMNantahala Capital Management
- KMKalehua Capital Management
Venrock
Balyasny Asset Management
Driehaus Capital Management
Affinity Asset Advisors- LMLynx1 Capital Management
ADAR1 Capital Management
Other known investors9 additional known investors
Blue Owl Capital
Deep Track Capital
Frequency Therapeutics
Marine Biological Laboratory
Platanus
Point72 Ventures
Rock Springs Capital
The University of Chicago
Tri Locum Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Korro Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Korro Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.